Bryxta 300mg Injection
Prescription Required
Marketed By
zydus
Pack of
12ml/Vial
Salt Composition
Bevacizumab
Storage
Keep in cold place
₹9600₹28995
66.89% Off
Inclusive of all taxes
1
Bryxta 300mg Injection
Delivering To: —
Description
Bryxta 300mg tablet is a targeted drug prescribed by the healthcare professional for the treatment of colorectal cancer in adult men and women. Its active ingredient is Bevacizumab, a monoclonal antibody. It works by blocking the vascular endothelial growth factor ( VEGF), a protein which stimulate the development of blood cells and the process called angiogenesis. Doctors do not prescribe this medication to adults children under the age of 18 to ensure safety. Proper medical attention is required while taking the medication as it may cause side effects.
Indication
Colorectal cancer
Common Side Effects
• Headache
• Vision changes
• Confusion
• Severe allergic reactions
• High Blood pressure
• Numbness in hands or feet
• Weakness and lack of energy
• Diarrhea, nausea, vomiting, abdominal pain
• Constipation
• Loss of appetite
Dosage And Duration
Bryxta 300mg tablet should taken under the strict supervision of a healthcare professional. Taking in the wrong way may cause severe side effects. Follow the prescribed dosage as recommended and schedule exactly as advised by the doctor. Do not chew or crush the medication as it may reduce its effectiveness and interfere with how the medication is absorbed in the body.
Mechanism Of Action
Colorectal cancer is caused by genetic mutations in colon cells, causing them to grow uncontrollably and become cancerous. Bryxta 300 mg tablet contains Bevacizumab, a VEGF inhibitor that blocks vascular endothelial growth factor (VEGF), which tumors use to form new blood vessels. The medication helps slow tumor growth, reduce the risk of metastasis, and complement other cancer treatments.
Safety Advice
Alcohol
unsafe
Patients should avoid alcohol while taking Bryxta 300mg Injection because it interrupt with the treatment and may cause dangerous fluctuations in blood pressure.
Driving
consult your doctor
Consult the doctor if Bryxta 300mg Injection should be taken or not while the patient is on the treatment.
Pregnancy
consult your doctor
Bryxta 300mg Injection is not taken by pregnant women unless prescribed, as the medicine can affect the newborn baby.
Breast Feeding
unsafe
Women who breastfeed their child should avoid using Bryxta 300mg Injection as it may pass into breast milk and affect the baby.
Kidney
caution
Bryxta 300mg Injection is not used by kidney patients without medical supervision because the medicine can interrupt with the kidney function.
Liver
consult your doctor
Consult a doctor before taking Bryxta 300mg Injection if you are a patient of liver cancer, as liver function can affect the metabolism and effectiveness of the medication.
Faqs
Bryxta 300mg Injection show common as well as severe side effects, including- Joint swelling, fatigue, nausea, urinary tract infection, diarrhea and high blood pressure, consult the healthcare provider if the symptoms persist.
Patient of colorectal cancer can take benefit from Bryxta 300mg Injection, doctors prescribed this medication based on the patient condition and stage of cancer.
Bryxta 300mg Injection salt composition is Bevacizumab which helps to reduce the formation of cancer cells in the body.
Bryxta 300mg can be used in combination of other treatment but regularly follow up the appointments to ensure safety and effectiveness.
Bryxta 300mg Injection should be taken with or without food, depend on the patient response to the treatment and doctor prescription.
References
• McCormack, P. L., & Keam, S. J. (2008). Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs, 68(4), 487-506.
• Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., ... & Liang, S. X. (2011). Incorporation of bevaciz
• Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 114(5), 855-859.
• Keating, G. M. (2014). Bevacizumab: a review of its use in advanced cancer. Drugs, 74(16), 1891-1925.
• Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery, 3(5), 391-400.
Related Products
MARKETER DETAILS
zydus
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.